These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 22848094)

  • 1. Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors.
    Ghadimi MP; Lopez G; Torres KE; Belousov R; Young ED; Liu J; Brewer KJ; Hoffman A; Lusby K; Lazar AJ; Pollock RE; Lev D
    Mol Cancer Ther; 2012 Aug; 11(8):1758-69. PubMed ID: 22848094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
    Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
    Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.
    Yu P; Laird AD; Du X; Wu J; Won KA; Yamaguchi K; Hsu PP; Qian F; Jaeger CT; Zhang W; Buhr CA; Shen P; Abulafia W; Chen J; Young J; Plonowski A; Yakes FM; Chu F; Lee M; Bentzien F; Lam ST; Dale S; Matthews DJ; Lamb P; Foster P
    Mol Cancer Ther; 2014 May; 13(5):1078-91. PubMed ID: 24634413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma.
    Mirzoeva OK; Hann B; Hom YK; Debnath J; Aftab D; Shokat K; Korn WM
    J Mol Med (Berl); 2011 Sep; 89(9):877-89. PubMed ID: 21678117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
    Dai C; Zhang B; Liu X; Ma S; Yang Y; Yao Y; Feng M; Bao X; Li G; Wang J; Guo K; Ma W; Xing B; Lian W; Xiao J; Cai F; Zhang H; Wang R
    Endocrinology; 2013 Mar; 154(3):1247-59. PubMed ID: 23384836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
    Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pan erbB inhibitor PD168393 enhances lysosomal dysfunction-induced apoptotic death in malignant peripheral nerve sheath tumor cells.
    Kohli L; Kaza N; Lavalley NJ; Turner KL; Byer S; Carroll SL; Roth KA
    Neuro Oncol; 2012 Mar; 14(3):266-77. PubMed ID: 22259051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autophagy blockade enhances HDAC inhibitors' pro-apoptotic effects: potential implications for the treatment of a therapeutic-resistant malignancy.
    Lopez G; Torres K; Lev D
    Autophagy; 2011 Apr; 7(4):440-1. PubMed ID: 21224727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Targeting of AKT and mTOR Inhibits Proliferation of Human NF1-Associated Malignant Peripheral Nerve Sheath Tumour Cells In Vitro but not in a Xenograft Mouse Model In Vivo.
    Schulte A; Ewald F; Spyra M; Smit DJ; Jiang W; Salamon J; Jücker M; Mautner VF
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of PI3K and mTOR signaling pathways decreases human pancreatic neuroendocrine tumor metastatic progression.
    Djukom C; Porro LJ; Mrazek A; Townsend CM; Hellmich MR; Chao C
    Pancreas; 2014 Jan; 43(1):88-92. PubMed ID: 24263107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of AKT/ERK/CTNNB1 by DAW22 as a potential therapeutic compound for malignant peripheral nerve sheath tumor.
    Li XX; Zhang SJ; Chiu AP; Lo LH; Huang J; Rowlands DK; Wang J; Keng VW
    Cancer Med; 2018 Sep; 7(9):4791-4800. PubMed ID: 30112810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.
    Lopez G; Torres K; Liu J; Hernandez B; Young E; Belousov R; Bolshakov S; Lazar AJ; Slopis JM; McCutcheon IE; McConkey D; Lev D
    Cancer Res; 2011 Jan; 71(1):185-96. PubMed ID: 21084276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.
    Hu X; Xia M; Wang J; Yu H; Chai J; Zhang Z; Sun Y; Su J; Sun L
    Biomed Pharmacother; 2020 Sep; 129():110397. PubMed ID: 32585451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis.
    Xiao Y; Yu Y; Jiang P; Li Y; Wang C; Zhang R
    Cell Oncol (Dordr); 2020 Aug; 43(4):669-680. PubMed ID: 32382996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma.
    Liu T; Sun Q; Li Q; Yang H; Zhang Y; Wang R; Lin X; Xiao D; Yuan Y; Chen L; Wang W
    Mol Cancer Ther; 2015 Feb; 14(2):429-39. PubMed ID: 25504751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.
    Prasad G; Sottero T; Yang X; Mueller S; James CD; Weiss WA; Polley MY; Ozawa T; Berger MS; Aftab DT; Prados MD; Haas-Kogan DA
    Neuro Oncol; 2011 Apr; 13(4):384-92. PubMed ID: 21317208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway.
    Chen S; Yao L
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):323-334. PubMed ID: 33978839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.
    Smith MC; Mader MM; Cook JA; Iversen P; Ajamie R; Perkins E; Bloem L; Yip YY; Barda DA; Waid PP; Zeckner DJ; Young DA; Sanchez-Felix M; Donoho GP; Wacheck V
    Mol Cancer Ther; 2016 Oct; 15(10):2344-2356. PubMed ID: 27439478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.
    Watson AL; Anderson LK; Greeley AD; Keng VW; Rahrmann EP; Halfond AL; Powell NM; Collins MH; Rizvi T; Moertel CL; Ratner N; Largaespada DA
    Oncotarget; 2014 Mar; 5(6):1502-14. PubMed ID: 24681606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J
    Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.